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Abstract
With increasing numbers of patients with unresectable locoregionally advanced (LA) head and neck squamous
cell carcinoma (HNSCC) receiving cetuximab/radiotherapy (RT), several guidelines on the early detection and
management of skin-related toxicities have been developed. Considering the existing management guidelines for
these treatment-induced conditions, clinical applicability and standardization of grading methods has remained a
cause of concern globally, particularly in Asian countries. In this study, we attempted to collate the literature and
clinical experience across Asian countries to compile a practical and implementable set of recommendations for
Asian oncologists to manage skin- and mucosa-related toxicities arising from different types of radiation, with or
without the addition of cetuximab or chemotherapy. In December 2013, an international panel of experts in the
field of head and neck cancer management assembled for an Asia–Pacific head and neck cancer expert panel
meeting in China. The compilation of discussion outcomes of this meeting and literature data ultimately led to the
development of a set of recommendations for physicians with regards to the approach and management of
dermatological conditions arising from RT, chemotherapy/RT and cetuximab/RT, and similarly for the approach and
management of mucositis resulting from RT, with or without the addition of chemotherapy or cetuximab. These
recommendations helped to adapt guidelines published in the literature or text books into bedside practice, and
may also serve as a starting point for developing individual institutional side-effect management protocols with
adequate training and education.
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Background
Head and neck carcinomas account for 5 % of all can-
cers, and over 90 % are head and neck squamous cell
carcinoma (HNSCC) [1, 2]. The landscape of HNSCC
treatment has evolved over the past decade. Multiple fac-
tors feed into treatment decisions, and a multidisciplinary
team approach is important for making treatment deci-
sions. Historically, the standard nonsurgical treatment for
locoregionally advanced (LA) disease was radiotherapy
(RT) alone, which still is the standard treatment in some
parts of Asia along with cisplatin-based concurrent che-
moradiotherapy. Cetuximab, an anti-epidermal growth
factor receptor (EGFR) monoclonal antibody, was shown
to improve loco-regional control rates and survival in
combination with RT versus RT alone [3]. Cetuximab plus
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RT, therefore, further helped to provide an alternative
treatment option in the LA-HNSCC population. Based on
supporting literature and clinical practice, the main treat-
ment modalities for HNSCC are summarized in Fig. 1.
Epidemiological studies show an increasing incidence of
human papillomavirus (HPV)-associated oropharyngeal
cancer. HPV-associated HNSCC is recognized as a special
entity; patients with such tumours are often younger and
have better prognosis, therefore long-term toxicities of
therapy are a major issue [4]. Not only in such patients
[5], but in the overall management of LA-HNSCC,
reduction of treatment-related toxicities is generating
more attention, particularly where patient quality-of-life is
prioritised as part of the multidisciplinary treatment
approach. Concurrent chemoradiotherapy (CCRT) with
high-dose cisplatin is known to cause considerable early
[6] and late [7] toxicities in HNSCC cases, and that is even
the case when using weekly low-dose schedules [8, 9]. The
aforementioned Bonner trial,3 comparing cetuximab/RT
to RT alone in LA-HNSCC patients, showed superiority of
the cetuximab/RT arm with respect to loco-regional
control (at 3 years, 47 % versus 34 %) and overall survival
(at 5 years, 46 % versus 36 %) after a median follow-up of
54 months. An interesting finding of that study was the
remarkable compliance to the cetuximab/RT treatment,
with an adherence rate of 90 % [10]. With the exception
of acneiform eruptions and infusion reactions, the inci-
dence of grade 3 or greater toxic effects, including muco-
sitis, did not differ significantly between the two arms of
the study. A better compliance with cetuximab/RT than
with cisplatin-based CCRT was also observed in a direct
comparison of both approaches after cisplatin-based
induction chemotherapy (ICT) in the TREMPLIN study, a
larynx preservation study in patients with larynx and
hypopharynx cancer who were candidates for total laryn-
gectomy [11]. Interestingly, the better compliance was ob-
served despite the fact that a higher incidence of grade 3
in-field skin toxicity was observed. Japanese oncologists
also used an opioid-based pain control program more
systematically to improve compliance with CRT in head
and neck cancer patients [12].
With an increasing number of patients with un-
resectable LA-HNSCC receiving cetuximab/RT, several
guidelines on the early detection and management of
skin-related toxicities have been developed, which ad-
dress pathogenesis, pathophysiology and clinical aspects
in patients experiencing these side effects [13, 14]. At
the same time, as mentioned by several oncologists, the
reported rates of skin toxicity and mucositis with cetuxi-
mab/RT in daily practice may be higher than that
reported in the pivotal studies with this combination
[15, 16]. Given the existing management guidelines for
these treatment-emergent conditions, clinical applica-
bility and standardization of the grading methods has
remained a cause of concern globally, particularly in
Asian countries, because of racial and ethnic variations
in tumour subsites, causative factors, skin conditions,
hospital radiotherapy set-ups, patient management pro-
tocols and so on. Notwithstanding the fact that, thus far,
no robust data can be found in the literature in favour of
a link between ethnic differences and variations in skin
sensitivity to cetuximab; such a relationship might ex-
plain the higher incidence and severity of cutaneous re-
actions observed consistently in the Asian population
compared with Western patient cohorts. Therefore, this
study was developed in an attempt to compile literature
and clinical experience from across Asian countries, to
determine a practical and implementable set of recom-
mendations for Asian oncologists to manage skin- and
mucosa-related toxicities caused by different types of
radiation, with or without the addition of cetuximab or
chemotherapy.
Methods
In December 2013, an international panel of experts in
the field of head and neck cancer management convened
for an Asia–Pacific head and neck cancer expert panel
meeting in China. The panel comprised members who
Fig. 1 Main nonsurgical treatment modalities for HNSCC based on literature and clinical practice. RT, radiotherapy; CCRT, concurrent chemoradiotherapy;
CT, chemotherapy
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are experts in the fields of head and neck cancer medical
oncology and radiation oncology. As pre-meeting
preparation, the panel members participated in a pre-
meeting survey to assess the occurrence of skin and mu-
cosal toxicities observed with cetuximab/RT treatment,
along with the management practices followed in their
respective practice, institute or hospital. These pre-
meeting survey results were used as the basis for the
expert panel discussion, which ultimately led to the
development of a set of recommendations for physicians
with regards to the following:
 Approach to and management of dermatological
conditions arising from RT, CCRTand cetuximab/RT).
 Approach to and management of mucositis resulting
from radiation, with or without the addition of
chemotherapy or cetuximab.
During this whole process, it was kept in mind that
treatment strategies are changing over time and that
survivorship issues are becoming more prominent.
Reducing late toxicities is thereby of crucial importance.
Radiation dermatitis and skin toxicity from cetuximab/RT
Literature review and clinical experience
Anti-EGFR treatment outcomes in a variety of solid can-
cers, including HNSCC, correlate with the degree of skin
rash [17]. The acneiform skin eruptions observed with
cetuximab may be better described as “folliculitis” be-
cause of its pathophysiology and distribution areas.
Overall, skin rashes are manageable and reversible [18].
In the Phase II TREMPLIN study, the cetuximab/RT
arm showed a higher number of patients with grade 3–4
in-field skin toxicity than the cisplatin-based CCRT arm.
However, not only the occurrence of the in-field derma-
titis differs, but also the type of in-field skin toxicity.
There are both pathophysiological and clinical differ-
ences in the dermatitis induced by RT alone, CCRT and
cetuximab/RT (Table 1) [18].
Distinguishing characteristics of cetuximab/RT-associ-
ated dermatitis consist of marked xerosis, an intense
inflammatory response in the sub-epidermis (indicating
an immunological- and cytokine-mediated response at
the level of the epidermis and dermis), and the inhibition
of anti-microbial peptides, which increases the risk of a
superinfection. There may be loss of continuity of the
epidermis, leading to exudation of fluids and formation
of crusts. These crusts are comprised of inflammatory
exudate and exfoliated corneocytes; they compromise
the healing of the affected area, and are susceptible to
sustained microtrauma and are thereby prone to abra-
sion, bleeding, discomfort and/or pain and risk of super-
infection. Contrary to what is observed with cetuximab/
RT, crusting is typically absent with radiation alone or
with CCRT. With CCRT, the dermatitis is associated
with a dry desquamation and exfoliated corneocytes,
occurring before moist desquamation and exposure of
the underlying dermis. With higher dosages of radiation,
as seen with modern and novel methods of irradiation,
skin necrosis and ulceration of dermis may be noted
frequently. The cetuximab/RT-associated dermatitis ap-
pears to be more severe than that with RT alone or
CCRT, and has an earlier onset at around 1–2 weeks of
starting treatment. However, it also resolves more rap-
idly, approximately 1–2 weeks after the completion of
treatment (clinical practice).
There is a need to follow a different grading system for
radiation dermatitis, to distinguish that which arises from
cetuximab/RT and that which occurs with RT alone. The
new grading system and management guidelines pub-
lished in Annals of Oncology help to understand, assess,
evaluate and manage cetuximab/RT-induced radiation
dermatitis more successfully [19]. While there is currently
no validated, standardized, uniform method of grading,
thus preventing the development of radiation dermatitis,
intervention at an early stage is crucial for effective
management.
In general, patients with grade 1–3 reactions can be
managed as outpatients, although this should be decided
on an individual patient basis. Initially, patients must be
monitored weekly by the management team for signs of
early skin reactions (for the first 2 weeks), until the first
sign of erythema, at which point monitoring should be
more frequent (at least twice weekly) and intense.
Patients developing severe early erythema should be
Table 1 Pathophysiological and clinical differences in radiation
dermatitis with RT/CRT and cetuximab + RT
RT/CRT alone Cetuximab + RT
Pathophysiological (for more details, please refer to text)
Clinical
Onset of dermatitis is within
3–5+ weeks of treatment
Onset of dermatitis is within 1 or
2 weeks of treatment
No crusting Crusting is present, which can result
in sustained microtrauma, bleeding,
and discomfort and can lead to
infection
# Images courtesy of Dr. Merlano
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monitored closely throughout treatment. Bypassing early
monitoring of dermatitis can eventually lead to abrupt
discontinuation of therapy, thereby jeopardizing a
beneficial outcome of the treatment. Continuation of
cetuximab treatment depends on the grade of radiation
dermatitis observed. In cases of grade 3 dermatitis, it
may be appropriate to consider a brief interruption for
4–5 days in the treatment of severe grade 3 dermatitis,
especially with suspected superinfection or with a radi-
ation doses as low as 50 Gy (or a cumulative dosage
reaching a total of 50 Gy). Cetuximab can be restarted
as soon as the severity of dermatitis reduces to grade 2.
While grade 4 dermatitis is considered to be a rare
event, cetuximab, and/or other systemic anticancer
treatments, should be discontinued.
Overall, patients should be provided with written in-
formation on how to manage their skin reactions, and
the use of a nursing diary for the same purpose is rec-
ommended. Management of dermatitis can be catego-
rized under general and grade-specific management
(Table 2) [18]. An expert team, comprising of a derma-
tologist and nursing care, is crucial in symptomatic and
supportive care to adequately monitor and manage radi-
ation dermatitis.
General management of radiation dermatitis, as men-
tioned in Table 2, includes [18] skin hygiene (washing
no more than twice a day with pH 5 soap and clean
towels); shaving to reduce folliculitis risk; transparent
dressings to allow monitoring for infection; debridement
to reduce superinfection risk; monitoring for systemic
inflammation; and avoidance of aloe vera, scratching,
local trauma, exposure to sunlight and dressings that
might be responsible for deviations from treatment pro-
tocols in terms of radiation dose reduction. According
to Japanese experience, radiation dermatitis can be man-
ageable by gentle washing and moistening of the wound-
healing environment [20].
The panel found deficiencies in the management of
radiation dermatitis that still remain to be addressed,
including the following: inconsistent toxicity criteria;
subjective grading of reactions that impedes the inter-
pretation of toxicity findings; little evidence to indicate
that any of the currently available products can prevent
the development of these skin reactions; and insufficient
understanding of the biological mechanisms responsible
for the skin toxicity of individual agents, as a greater un-
derstanding would lead to the development of rational
and more effective management strategies for the skin
reactions of patients receiving cetuximab/RT.
Results
Recommendations based on clinical practice
The recommendations are based on prevention, early
warning signals, management of radiation dermatitis and
dose adjustment for cetuximab and radiation. In clinical
practice, although the overall reporting of grade and
severity of radiation dermatitis in patients receiving
cetuximab/RT is similar to that reported in the Bonner
trial, a certain amount of variation in the grading cannot
be denied. This highlights subjective differences includ-
ing temporal, interpersonal or treatment biases that may
be occurring in the assessment of this condition. This
needs to be addressed by a standardized and more ob-
jective assessment tool.
The group indicated that it is important to assess
exactly when the toxicity starts to develop and not only
to look for the maximum grade of toxicity. If skin reac-
tions are already seen in the first or second week of
therapy, one would expect more toxicity than when skin
reactions are observed for the first time in the third or
fourth week of treatment. Moreover, factors like tem-
perature (hot summers/winters) may also affect the
grading system. Patients may be assessed by different
doctors/observers at different times, which may lead to
different grading in the same patient. Even if the criteria
are listed in the text, perception may differ between dif-
ferent physicians. The subjective nature of assessment
may allow for bias as some physicians are cautious or
sometimes less experienced, while others may be more
experienced when dealing with the same condition.
Based on the above discussions, the group agreed that
there is a need for a new objective method of classifica-
tion/grading system of radiation dermatitis; for example,
having a standard image of each grade. A new grading
system may be developed in Asian countries, depending
upon ethnic variations, based on crusting, infection and
interindividual variations such as skin colour. Any im-
ages must be obtained under standard conditions for the
hospital or country for such assessments and grading.
The guidelines for grading of the radiation dermatitis
must take into account climatic (i.e. tropical, sub-
tropical etc.) and geographical (i.e. altitude, ethnic varia-
tions etc.) factors. A multidisciplinary approach should
be considered in defining a new clinically assessable
grading system in Asia.
Recommendations for management of skin conditions
The expert panel indicated that prophylactic treatment
is important for both the development of skin eruptions
and prevention of superinfection. Immunological reac-
tion and superinfection are two important factors to be
considered in the treatment of cetuximab/RT-induced
radiation dermatitis. Antihistamines and antibiotics can
be considered for the same. Inflammatory reaction is
critical in the pathophysiology of cetuximab/RT-induced
radiation dermatitis. The panel members recommended
against empiric use of prophylactic oral antibiotics and
oral corticosteroids, however consideration may be given
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on a case-by-case basis for oral medications to achieve
symptom control and prevent further aggravation of the
condition.
This decision must be taken based on the clinical
assessment and judgement of the physician after con-
sultation with a dermatologist. Maintenance of hygiene
Table 2 Radiation dermatitis: grading and general management recommendations
Grade of radiation
dermatitis













other than skin folds and
creases; bleeding induced
by minor trauma or
abrasion
Skin necrosis or ulceration






Maintain hygiene and gently clean and dry skin in the radiation field shortly before radiotherapy
Topical moisturisers, gels, emulsions and dressings should not be applied shortly before radiation treatment as they can




Use of a moisturiser is
optional







cream) may be used
occasionally
In the absence of clinical signs of infection, one or
combinations of the following topical approaches may
be used:
Requires specialised
wound care with the
assistance of the radiation
oncologist, dermatologist
and nurse, and should be
treated on a case by case
basis
• - Drying gels, possibly with the addition of antiseptics
(e.g. chlorhexidine-based creams)
• - An anti-inflammatory emulsion, such as trolamine
• - Hyaluronic acid cream
• - Hydrophilic dressings, applied after radiotherapy to the
cleaned, irradiated area, which may provide
symptomatic relief
• - Zinc oxide paste, if easy to remove prior to
radiotherapy
• - When used, silver sulfadiazine or beta glucan cream
should be applied after radiotherapy (possibly in the
evening) after cleaning the irradiated area
• - Where infection is suspected:
• - The treating physician should use best clinical
judgement for identifying infection, including the
consideration of swabbing the area for identification of
the infectious agent
• - Topical antibiotics (should not be used
prophylactically)
• - Doxycycline is not recommended at this stage
• - Blood granulocyte counts should be checked,
particularly if the patient is receiving concomitant
chemotherapy
• - Blood cultures should be carried out if there are
additional signs of sepsis and/or fever
Management team Can be managed
primarily by nursing staff







Should be managed primarily by a wound specialist,
with the assistance of the radiation oncologist, medical
oncologist (where appropriate), dermatologist and nurse,
as required
Skin reactions should be
assessed at least once
a week
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and careful cleaning of the skin were considered the best
methods for prevention of severe skin toxicities. These
measures are especially important in patients who may
have certain predispositions that categorize them as high
risk for development of severe skin toxicities, such as
having a small posture with a relatively short neck, skin
folds in the neck, moist sweaty skin, and use of an
immobilization mask. Education of both patient and
caregiver is of utmost importance in this condition. For
prevention, no clear documentation in the literature or
practice exists that can be recommended for all cases.
Therefore, it is important that a multidisciplinary ap-
proach is followed while designing protocols to manage
such conditions. Practice guidelines recommended by
the Asian experts are summarized in Table 3, based on
guidelines listed in Table 2.
Based on the above discussions, the expert panel rec-
ommended some preventive measures that are practiced
by almost all of the attending experts:
 Physician and patient education for skin care.
 Maintaining clean and dry skin, and avoiding
perspiration during and especially after exposure to
radiation dosing; the skin lesion with dermatitis
should be kept moist.
 No viscous creams or jellies to be applied within the
field of radiation during the radiation phase.
 Close monitoring once a week during start of
therapy; and with emergence of erythema,
monitoring must be more frequent up to twice a
week, with utmost attention to early management
strategies of the condition.
The expert panel overall agreed to the radiation derma-
titis “management” guidelines laid down in literature
(Table 2). Topical steroids may be necessary for grade 2
and 3 toxicity but should not be administered for a long
time. The feasibility of its use should be assessed by a
multidisciplinary team involving dermatologists at the
treating centre. Alternatively, the combination of topical
glucocorticosteroids plus local antiseptics/antibiotics
might be useful. Doxycycline, as an anti-inflammatory
agent with antibiotic properties, is worth considering on a
case-by-case basis in prevention as well as in grade 1–2
severity, to prevent further progression to grade 3 or
higher.
However, as mentioned earlier, dermatitis resulting
from RT alone and that induced by cetuximab plus radi-
ation (in the irradiated field), have different pathophysio-
logical mechanisms. As cited by Russi EG et al. [19], the
grading and management of radiation dermatitis is often
not applicable to radiation in-field dermatitis as it does
not include the associated side effects of cetuximab, and
vice versa, the toxicity grading and management of the
systemic cetuximab may not be applicable when the re-
actions are confined to a limited skin surface, as seen in
the irradiated field. These issues can explain the different
‘in-field toxic effect’ rates reported in different studies
and in clinical practice, also affecting management of
the condition. Based on this observation and experience,
Russi et al. proposed a grading system and recommenda-
tions for the management of skin conditions arising
from cetuximab plus radiation in a ‘Letter to Editor’
article published in the Annals of Oncology in July 2013.
The expert group recommended that this type of grad-
ing system (Table 4) may be more pragmatic in clinical
practice and should be considered when managing cases
of cetuximab/RT-induced dermatitis.
The expert panel proposed that the dose reduction
scheme for cetuximab-induced > grade 3 skin reactions
(mainly acne-like rash occurring outside the radiation
field) may also be valid in cetuximab/RT-induced in-
field dermatitis (see also Fig. 2). The panel opined that
in radiation dermatitis grade 3, cetuximab may be briefly
interrupted when occurring at <50 Gy. In grade 4
radiation dermatitis, cetuximab may be omitted until
Table 3 Common clinical practices for management of radiation dermatitis in Asian countries
Grade 1 Grade 2 Grade 3 Grade 4
Local treatment • No treatment is
required
• Keep the site clean and dry • Keep the site clean and dry • Keep the site clean and dry
• Avoid rubbing and
maintain moisture and
hygiene
• Topical treatment with
antiseptics/antibiotics/steroids
is recommended
• Topical treatment with
antiseptics/antibiotics/steroids
is recommended
• Topical treatment with
antiseptics/antibiotics/steroids
is recommended
• Topical treatment with
antiseptics/antibiotics/
steroids may help
Systemic treatment • No treatment is
required
• No treatment is required • Oral antibiotics, pain-killers,
corticosteroids or antihistamines
for symptom relief
• Oral antibiotics, pain-killers,
corticosteroids or antihistamines
for symptom relief
• Regular monitoring is
recommended
• Oral antibiotics, pain-killers,
corticosteroids or antihistamines
for symptom relief
• Temporary discontinuation or
delay of cetuximab treatment
• Temporary discontinuation of
cetuximab and radiation
treatment
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Table 4 Proposal of a new grading system for bio-radiation dermatitisa
TERM G1 G2 G3 G4
Dermatitis Bio-radiation Faint erythema or dry
desquamation; and
lesions due to bio-
treatment (e.g. xerosis,
papules, pustules, and
other clinical signs) which
may or may not be
associated with symptoms




and creases; lesions due
to bio-treatment (e.g.
crusts, papules, pustules,
and other clinical signs)
mostly confined to less
than 50 % of radiated
area; bleeding lesions
with friction or trauma.
Moist desquamation in
areas other than skin folds
and creases; extensive
(>50 % of involved field)




associated to bleeding by
minor trauma or abrasion.
Life-threatening
consequences; skin
necrosis or ulceration of full
thickness dermis; extensive
(>50 % of involved field)



















Topical and oral therapy
indicated
Topical and oral therapy
indicated; dressing and
wound indicated;












Evaluate the need for
daily assessment Closely
monitor signs of local or
systemic infection For
grade 3 reactions








until the skin reaction has
resolved to at least grade
2 In the case of severe
superinfection, consider
the use of i.v. antibiotics if
unresponsive to oral
antibiotics
aAdapted from references 18 and 19
Fig. 2 Pathobiology perspective: a multiple mechanism model. # Image courtesy of Keefe and Sonis. NB: The upregulation and message generation
phase involves the activation of a number of signalling pathways and transcription factors, most importantly NFκB, which in turn mediates gene
expression and synthesis of various inflammatory molecules including proinflammatory cytokines. Signal amplification is the third phase of mucositis
development where the inflammation signal is further amplified as a consequence of proinflammatory cytokines, with subsequent further tissue
damage as a result of increased apoptosis
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resolution to grade 2. Radiotherapy should only be
stopped in cases of grade 4 radiation dermatitis, which is
fortunately rarely seen.
Temporary interruption or discontinuation of cetuxi-
mab treatment while waiting for ≥ grade 3 radiation
dermatitis to resolve to grade 2 does not require a repeat
loading dose of cetuximab to be administered in the ma-
jority of cases, because this resolution (downgrading), as
documented in the guidelines, generally occurs within a
week or two of cetuximab dose interruption or discon-
tinuation. However, with good debridement, skin care,
hydrocolloid gels, and topical antibiotics, dose delays in
cetuximab or radiation may be completely avoided in
most cases.
Mucositis arising from cetuximab/RT
Literature review and clinical experience
Between 30 % and 60 % of patients receiving RT for
HNSCC may develop oral mucositis, and greater than
90 % of patients receiving CCRT are affected [21, 22].
The degree and duration of mucositis in patients treated
with RT are related to radiation source, cumulative dose,
dose intensity, volume of radiated mucosa, smoking,
alcohol consumption, and oral hygiene [23, 24].
The exact pathophysiology of mucositis is not com-
pletely understood. Principally, it is thought to have two
mechanisms: direct mucositis and indirect mucositis,
caused by chemotherapy and/or radiation therapy.
1. Direct mucositis: The epithelial cells of the oral
mucosa undergo rapid turnover, usually every 7 to
14 days, which makes these cells susceptible to the
effects of cytotoxic therapy. Both chemotherapy
and radiation therapy interfere with cellular mitosis
and reduce the ability of the oral mucosa to
regenerate [21].
2. Indirect mucositis: Oral mucositis can also be caused
by the indirect invasion of Gram-negative bacteria
and fungal species. Patients are at increased risk of
oral infections when they are neutropenic, and this
usually happens when indirect stomatotoxicity
appears [24].
In the literature, pathogenesis of mucositis has been
described in four phases [25]: an inflammatory/vascular
phase, an epithelial phase, an ulcerative/bacteriologic
phase and a healing phase. The first signs of mucositis
are white appearances of the mucosa such as hyperkera-
tinization and edema of the mucosa and formation of
pseudomembranes, and red appearances resulting from
hyperemia and epithelial thinning such as vascular
damage and endarteritis. With 180–220 cGy radiation
per day, mucositis with erythema is noted within 1 to
2 weeks and increases throughout the course of therapy
to a maximum in 4 weeks, with persistence until 2 or
more weeks after the completion of therapy.
A multiple mechanism model was suggested by Keefe
and Sonis [26], which divided the process into five stages:
initiation, upregulation and message generation, signalling
and amplification, ulceration and healing (Fig. 2).
Toxicity grading of oral mucositis according to WHO
and NCI-CTC criteria (version 4.0) [27] is shown in
Fig. 3. These are commonly-used assessment scales to
grade the severity of oral mucositis that might impact
negatively on compliance of treatment guidelines in
terms of dose intensity. Various risk factors for oral mu-
cositis are chemotherapy dose and protocol, concomi-
tant head and neck RT, microtrauma, pretreatment oral
status, and patient factors such as lifestyle and habits.
Various differential diagnoses also need to be considered
because some conditions including oral thrush, aphthous
ulcer, hypovitaminosis, and chronic trauma, such as
denture-related trauma, can coexist in immunocom-
promised patients.
Basic oral care guidelines have been updated for the
prevention and treatment of mucositis, including [28]:
dental assessment, and care prior to treatment, during
treatment and during follow-up; basic oral care includ-
ing an ultra-soft toothbrush with regular replacement of
the toothbrush; bland rinses; promoting mucosal moist-
urization and protection; and regular check-up for
fungal, bacterial or viral infections at follow-ups. For
prevention, alternative therapies that can be given in-
clude vitamins A, E, and B12, folate, diet supplements,
glutamine, aloe vera and PV701, a milk-derived protein
extract. Management of oral mucositis can be systemic
and topical, as described in Table 5.
As observed in the Bonner trial [3], the incidence of
grade 3–4 mucositis and dysphagia did not differ in
the cetuximab/RT arm vs. RT alone, with 55.8 % vs.
51.9 % , and 26 % vs. 29.7 % respectively; while in the
TREMPLIN study, the occurrence of grade 3–4 muco-
sitis was 45 % with cetuximab/RT versus 47 % with
CCRT. Asian clinical studies in Chinese [29] and
Japanese [16, 30] populations have also shown a
similar or sometimes worse outcome of cetuximab
addition to RT, versus RT alone, upon the occurrence
of mucositis in these patients.
Despite that, there is a lack of sufficient literature to
differentiate pathophysiological differences between
mucositis arising from RT alone, CCRT and cetuximab/
RT. Clinically, the nature and distribution of mucositis
with cetuximab/RT is found to be similar to that with
RT and CCRT. However, in the mucositis observed with
cetuximab/RT, it seemed that some mucosal inflamma-
tion appeared in non-irradiated areas, but effects from
radiation scatter cannot be ruled out in these cases,
although this was not found in the Bonner study [3].
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Identification of risk factors is one of the crucial
aspects related to mucositis. Risk of mucositis has clas-
sically been directly associated with modality and inten-
sity of radiation [31, 32]. Clinical perception, though not
clearly supported in literature, has indicated that
combination therapy, either with cisplatin or with cetux-
imab with RT, may increase the severity of oral mucosi-
tis. Incidence and severity of acute mucosal toxicity has
not generally been significantly reduced by utilization of
state-of-the-science radiation technologies (for example,
volumetric-modulated arc therapy). Genetic polymor-
phisms or ethnic and racial intrinsic sensitivities may
play a role. Patient-related risk factors such as co-
morbidities (for example, malnutrition and diabetes) and
lifestyle habits (smoking, tobacco chewing, poor oral
hygiene, and alcohol) can contribute, and significant
salivary hypofunction/xerostomia and/or antiemetic drugs
may cause increased discomfort from oral mucositis.
Discussion and recommendations based on clinical
practice
Based on the above discussions, the group of experts
proposed to categorize patients at risk of developing
severe mucositis, as shown below:
 Patient-related risks: smoking, poor hygiene, clinical
co-morbidities (such as diabetes, superadded
candidal thrush).
 Tumour-related risks: site-related such as the
oropharynx; tumours close to the midline are more
related to mucositis than unilateral tumours.
 Treatment-related risks: radiation dose intensity,
technique-related.
Table 5 Management of oral mucositis
Systemic Topical
1. Pain management Diluting agentsb: Saline,
bicarbonate rinses, frequent
water rinses, dilute hydrogen
peroxide rinses
• Analgesics: WHO ladder Topical anaestheticsb: Dyclonine
HCl, xylocaine HCl, benzocaine













• Amifostine: Scavenge free
radicals
3. Biologic Response Modifiersa
• G-CSF, GM-CSF, Keratinocyte
Growth Factor
aMore relevant in Bone Marrow Transplant cases and not crucial in
radiotherapy patients
bMost practiced and accepted form of topical therapy
cThough mentioned in-frequently in literature and case discussions, they have
failed to generate sufficient impact in routine practice
Fig. 3 Toxicity grading of oral mucositis according to WHO and NCI-CTC criteria (CTCAE 4.0)
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Grading of mucositis
Similar to radiation dermatitis, the expert group opined
that no single grading system can completely address
the grading of mucositis adequately and in a reprodu-
cible manner. In the event of one or multiple differential
diagnoses co-existing with oral mucositis, the grading
becomes highly subjective. Based on the above discus-
sion, and similar to a need for having a standardised
grading system for mucositis, the group recommended
that a photographic method of assessing the severity of
mucositis will be crucial for correlating the correspond-
ing mucositis severity assessment criteria such as those
of WHO and NCI-CTC.
Management of mucositis
Prevention
Quoting from literature [33] and institutional experience
[34], a considerable amount of debate and varied schools
of thoughts exist on the optimal and correct radiation
techniques and modalities that truly benefit the patients,
spare normal organ function and avoid exposure to un-
necessary toxicity.
Although understanding and handling of newer radiation
techniques is still being improved and can be mastered
effectively with increasing experience, there is more muco-
sitis with newer radiation technology. Mucositis may be
more intense with volumetric arc-related technique/IMRT
as compared with 3D-CRT in certain cases, because of the
greater area of radiation exposure and hence increased
damage to mucosa, especially in cases of bilateral nodal in-
volvement or bulky primary tumours. When combined
with cetuximab, there appears to be more lesions in the
mucosa resulting from IMRT in clinical practice. But at
the same time, it is also important to note that the poten-
tial advantage of saving the critical organs with newer tech-
nologies outweigh some of the manageable and transient
side effects resulting from them [34, 35].
In clinical practice, parenteral feeding is not encour-
aged unless there is aspiration or dramatic weight loss of
greater than 10 %. Stimulating the patient to swallow
naturally during the radiation treatment phase is always
useful and also protects the pharyngeal muscles from
long-term residual side-effects. Some centres also use
nasogastric tubes if required, rather than percutaneous
endoscopic gastrostomy (PEG), at an early stage to avoid
weight loss and nutritional deficiency from dysphagia.
Incidence of mucositis may be high in patients receiv-
ing induction chemotherapy regimens, such as the new
standard docetaxel-cisplatin-5-fluorouracil (TPF) regi-
men, followed by definitive CCRT. [36] Unlike in the
Bonner study, wherein almost 70 % of patients had a
good performance status, in daily practice cetuximab/RT
is often used in patients who are elderly, have a poor
performance status or have a contraindication for
cisplatin or cannot tolerate it. This may confound the
severity of mucositis that is seen in practice to that
observed in the Bonner study. The group concluded that
for such patients who are relatively frail compared with
the better performance status in patients enrolled in
studies, but eligible to receive intensive and planned
therapy, any form of combination therapy may be more
toxic [37, 38]. The group also concluded that for many
poor performance patients, radiation alone should be
sufficient, and the choice of cetuximab/RT versus CCRT
should predominantly be made in patients fit enough to
receive CCRT. Cetuximab/RT could further be consid-
ered as an option for poor performance patients who
despite that are deemed to need a combined approach.
Common clinical practices for management of mucositis
set by the Asian experts are summarized in Table 6.
Based on the above discussion, the group made a
few recommendations in the prevention of mucositis
as a general measure for radiation therapy with or
without concurrent systemic treatment, including
cetuximab:
 Physician and patient education for mucosal care.
 For prevention of mucositis, all experts
recommended to follow the MASCC [28] guidelines
in clinical practice. Adding saline and sodium
bicarbonate rinses to the prevention guidelines was
suggested. It was also mentioned that honey, used in
some parts of the world, may be an effective and
feasible option for preventing mucositis.
 Maintaining oral hygiene is of utmost importance in
preventing mucositis. Frequent mouthwash use is
also an important factor.
 Tobacco, betel nut-chewing, smoking etc. adds to
irritability and hence should be avoided as a
precautionary measure.
 Use of midline radiation blocks and three-dimensional
radiation treatment to reduce mucosal injury is
recommended.
 Chlorhexidine is not recommended for prevention
of oral mucositis in patients with solid tumours of
the head and neck and who are undergoing
radiotherapy.
 Antimicrobial lozenges are not recommended for
prevention of radiation-induced oral mucositis.
 Buccolingual guards, using hydroplastic material,
can be easily oriented and adapted to an existing
radiation stent, adding positional stability and
patient comfort; with adequate thickness of
material used, the guard can attenuate forward
and back scatter radiation, separate the adjacent
tissues from metal restorations, and protect the
oral mucosa from localized incidents of
mucositis [39].
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The group of experts agreed that the MASCC guide-
lines in general terms well address the management of
mucositis in patients receiving radiotherapy. These are
accepted and used in routine practice by all physicians,
and they offered a few recommendations to add to the
guidelines in practice. In the absence of any identified
pathophysiological differences between mucositis caused
by cetuximab/RT and that with radiation alone or CCRT,
the management would essentially remain the same. The
experts highlighted that symptom control is of utmost
importance in the management of mucositis, irrespective
of the grade. For example, adding oral opioids for pain
control in addition to local anaesthetic agents such as
lignocaine and xylocaine.
Since cetuximab does not appear to cause a significant
increase in mucositis occurrence compared with radi-
ation alone, it may be feasible to resume cetuximab ad-
ministration in cases of > grade 3 mucositis [3], as soon
as the situation is clinically under control. However, in
grade 4 mucositis cetuximab should be stopped, since at
that stage mucositis seems to be clinically even more
critical than radiation dermatitis. Radiation dosage
should not be compromised in such events, unless the
infection is of a very severe category or there is a grade
4 reaction that cannot be controlled by symptomatic
medications without or with discontinuation of cetuxi-
mab and in case of serious systemic infections.
In addition, patients may also be advised to follow
some simple daily habits that could reduce the dis-
comfort caused by mucositis, as follows [26]:
 Patients are encouraged to sit upright at a 90° angle
and lean their head slightly forward.
 Eat slowly. Food should be cut into small pieces and
chewed completely.
 Eat small meals at frequent intervals instead of
heavy meals.
 Food taken should be warm, or at room
temperature. Hot food and drinks should be
avoided. Similarly, crunchy foods such as potato
chips and nuts should also be avoided.
 Soft food is always encouraged. Finely chopped
cooked meat, fruits, and vegetables should be
taken. Patients can also try commercial baby
foods, which are nutritious, convenient, and very
easy to swallow. Milkshakes that are very high in
proteins can also be tried.
 Usage of straws will not only make drinking easy but
will also avoid direct contact with the affected
portion of the mouth.
 Do not talk while food is in the mouth.
 Acidic foods such as tomatoes, grapes, apple fruits
or juices, alcohol and tobacco, and spicy foods
should be avoided.
 To relieve the discomfort of dry mouth, patients are
asked to rinse mouth with water before and after
every meal.
Conclusions
With newer and emerging therapy options in the man-
agement of HNSCC, it is critical that treating physicians
are well aware of and updated on the assessment of
patient-, tumour-, treatment- and disease-related factors,
not just for selecting the most efficacious forms of treat-
ment but also the risk and beneficial aspects of these
Table 6 Common clinical practices for management of mucositis in Asian countries.
Grade 1 Grade 2 Grade 3 Grade 4
• Maintain oral hygiene • Maintain oral hygiene • Maintain oral hygiene • Maintain oral hygiene
• Frequent mouthwash use with
agents like betadine, sodium
bicarbonate
• Frequent mouthwash use with
agents like betadine, sodium
bicarbonate
• Frequent mouthwash use with
agents like betadine, sodium
bicarbonate
• Frequent mouthwash use with
agents like betadine, sodium
bicarbonate




anesthetics for pain relief




anesthetics for pain relief
• Systemic continuous use of
steroidal therapy for mucositis
prevention/therapy not
recommended
• Parenteral nutrition used only if
the bowel is not working or there
are serious contra-indications to
the placement of a device for
enteral nutrition
• Parenteral nutrition used only if
the bowel is not working or
there are serious contra-
indications to the placement of
a device for enteral nutrition • Stop radiation and cetuximab
till the condition is resolved
• Cetuximab dosing may be
interrupted for a week or two,
till the reaction has resolved to
grade 2
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modalities and agents. However, this should not discour-
age or dissuade physicians from adopting new forms of
therapy, but instead motivate them to better understand
the pathophysiology and underlying mechanisms in
action for every intervention or treatment approach. The
above discussions and recommendations by international
head and neck cancer treatment experts were based on
literature surveys and experience gained in clinical prac-
tice. The recommendations derived from the expert con-
sensus meeting will help to adapt guidelines published
in the literature or text books into bedside practice.
These recommendations may also serve as a starting
point for developing individual institutional side-effect
management protocols with adequate training and edu-
cation in the Asia–Pacific region.
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